News 2025
01.08.2025
UNITE4TB flagship trial completes first wave recruitment
Tuberculosis (TB) is a major threat to public health and is among the leading causes of death worldwide, according to the World Health Organization. The emergence of drug-resistant TB and current standard of long treatment regimens have increased the urgent need for new, more effective therapies.
25.07.2025
Global trial evaluates shortened treatment for highly drug-resistant tuberculosis
A major international clinical trial published this week in The Lancet Respiratory Medicine has assessed the efficacy and safety of a novel, shortened treatment regimen for patients with pre-extensively drug-resistant tuberculosis (pre-XDR TB)—a form of tuberculosis that is resistant to both rifampicin and fluoroquinolones.
17.07.2025
New study reveals alarmingly low treatment success rates for extensively drug-resistant tuberculosis in Europe
A landmark multinational study published in The Lancet Regional Health – Europe has revealed that only 40% of patients with extensively drug-resistant tuberculosis (XDR-TB) in the WHO European Region achieved successful treatment outcomes.
07.07.2025
How does resistance develop—and what can be done to preserve Antibiotic effectiveness?
Using laboratory experiments and mathematical calculations, researchers at the FZB have for the first time been able to define the areas in which the development of resistance to two important tuberculosis drugs is favored.
01.07.2025
European Advanced Course in Clinical Tuberculosis 2025 convenes global experts in Borstel Borstel, Germany
The European Advanced Course in Clinical Tuberculosis (EACCTB) 2025 concluded successfully this week, bringing together 120 clinicians, scientists, and public health professionals from 13 countries at the Research Center Borstel, Leibniz Lung Center. This premier 3-day event provided a comprehensive update on the clinical management and research developments in tuberculosis (TB), a disease that continues to challenge global health systems.